2011 Cancer Committee Members - Erlanger Health System

More documents

Recommendations

Info

Ten-Year Comparison of Major Site Groupings at Erlanger 21 Major Site Groupings Site 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Total Lung 157 174 164 186 164 147 139 149 151 130 1561 Breast 156 146 145 119 115 122 128 137 164 193 1425 Colorectal 58 74 81 93 86 69 78 64 52 53 708 Leukemia/ 65 75 64 59 69 69 67 51 62 65 646 Lymphoma Head/Neck 54 63 63 79 53 56 65 50 17 24 524 Cervix/Corpus 49 59 70 63 53 59 49 73 64 76 615 Uteri Brain 38 35 52 66 58 53 49 38 37 52 478 Prostate 44 33 26 14 16 19 26 53 54 59 344 Melanoma 28 35 21 26 35 23 29 25 26 27 275 Ovary 18 31 28 23 21 24 27 24 20 17 233 *Other Sites 186 205 176 213 210 190 290 184 208 191 2053 Total 853 930 890 941 880 831 947 848 855 887 8862 *All other Cancer Sites 2001 – 2010 Erlanger Health System Overview by Cancer Site Lung - 18% Breast - 16% Colorectal - 8% Leukemia & Lymphoma - 7% Head & Neck - 6% Cervix & Corpus Uteri - 7% Brain - 5% Prostate - 4% Melanoma - 3% Ovary - 3% All other sites - 23% The above statistics are based on analytic cases. Analytic cases - cases diagnosed at the accessioning facility and/or administered any of the first course of treatment, after the cancer registry’s reference date of 1998. Non-analytic cases - cases diagnosed elsewhere, accessioned elsewhere and/or all of first course of treatment administered elsewhere.
Prostate Cancer Prostate cancer is the most frequently diagnosed cancer in men, and for reasons that remain unclear, incidence rates are significantly higher in blacks than in whites. In 2010, 59 men were newly diagnosed and treated for prostate cancer at the Erlanger Health System. This was 7% of the total 887 analytic cases reported in 2010. Per the American Cancer Society, it is estimated that there will be 240,890 men newly diagnosed with prostate cancer in 2011 with an estimated 33,720 deaths from prostate cancer in 2011, making prostate cancer the second-leading cause of cancer death in men. The risks factors and symptoms are as follows: Research has shown that men with certain risk factors are more likely than others to develop prostate cancer. A risk factor is something that may increase the chance of getting a disease. Studies have found the following risk factors for prostate cancer. Age: Age is the main risk factor for prostate cancer and the chance of a male getting prostate cancer increases as he gets older. In the United States, about 63% of all prostate cancer cases are diagnosed in men aged 65 and older. This disease is rare in men under 45. Family history: A man’s risk is higher if his father, brother or son has been diagnosed with prostate cancer. Recent genetic studies suggest that strong familial predisposition may be responsible for 5-10% of prostate cancers. Race/ethnicity: Prostate cancer is more common among black men than white or Hispanic/Latino men. It is less common among Asian/Pacific Islander and American Indian/Alaska Native men. Certain prostate changes: Men with cells called high grade prostatic intraepithelial neoplasia (PIN) may be at increased risk of prostate cancer. These prostate cells look abnormal under a microscope. Certain Genome changes: Researchers have found specific regions on certain chromosomes that are linked to the risk of prostate cancer. Recent studies show if a man has a genetic change in one or more of these regions, the risk of prostate cancer may be increased. 22 Prostate Cancer Signs and Symptoms A man with early prostate cancer may not have symptoms. For those with more advanced disease, individuals may experience weak or interrupted urine flow, inability to urinate, difficulty starting or stopping the urine flow, the need to urinate frequently, blood in the urine, or pain/burning with urination. Advanced prostate cancer commonly spreads to the bones, which may cause pain in the hips, spine, ribs or other areas. Detection and Diagnosis Physicians may check for prostate cancer before a patient has symptoms. During an office visit, the physician will ask about the patient’s personal and family medical history and he will perform a physical exam. Patients may have one or both of the following tests: Digital rectal exam: the physician inserts a lubricated, gloved finger into the rectum and feels the prostate through the rectal wall. The prostate is examined for hard or lumpy areas. Prostate-specific antigen (PSA) blood test: this simple blood test allows laboratory technicians to determine PSA levels. Prostate-specific antigen (PSA) is a protein that is normally secreted and disposed of by the prostate gland. An elevated/high PSA level is commonly caused by BPH or prostatitis (inflammation of the prostate), but also may be caused by prostate cancer.
Page 1 and 2: Erlanger Health System 2011 Annual
Page 3 and 4: Adult Oncology The Erlanger Health
Page 5 and 6: 2011 Cancer Activities Erlanger’s
Page 7 and 8: 2011 Cancer Committee Members Non-P
Page 9 and 10: Participating Physicians 2011 Parti
Page 11 and 12: 2011 Cancer Conference Report Multi
Page 13 and 14: Radiation Oncology offers the lates
Page 15 and 16: Cancer Registry Report A Cancer Reg
Page 17 and 18: 2010 Geographic Distribution Reside
Page 19 and 20: 2010 Treatments for All Sites None
Page 21: Cancer staging plays a pivotal role
Page 25 and 26: Prostate Cancer Study 1998-2002 Obs
Page 27 and 28: Introducing CyberKnife ® ... the w

2011 Cancer Committee Members - Erlanger Health System

Create successful ePaper yourself

Delete template?

Save as template?